Nat. Immunol. 10, 778–785 (2009); published online 31 May 2009; retracted 12 July 2013
Despite many attempts to replicate these results, the authors have been unable to confirm the original data showing that IL-17 alone or in combination with B cell–activating factor controls the survival of human B cells (Fig. 1a,b). Because this weakens the conclusions of the paper, all the authors (except A.D. and P.T., who could not be contacted) now retract this paper.
Additional information
The online version of the original article can be found at 10.1038/ni.1741
About this article
Cite this article
Doreau, A., Belot, A., Bastid, J. et al. Retraction Note: Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 15, 894 (2014). https://doi.org/10.1038/ni0914-894a
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni0914-894a
This article is cited by
-
Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells
Acta Pharmacologica Sinica (2022)
-
Knockdown of RSAD2 attenuates B cell hyperactivity in patients with primary Sjögren’s syndrome (pSS) via suppressing NF-κb signaling pathway
Molecular and Cellular Biochemistry (2021)
